Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Yücel, Leonardo Fontenelle, S. Chamberlain (2019)
Introduction to the Special Issue on the Utility of Transdiagnostic Approaches for Developing Novel Interventions for Substance and Behavioural AddictionsNeuropsychology Review, 29
H. Alnajashi, Razan Jabbad (2020)
Behavioral practices of patients with multiple sclerosis during Covid-19 pandemicPLoS ONE, 15
R. Cutler, F. Fernandez‐Llimos, M. Frommer, Charlie Benrimoj, V. García-Cárdenas (2018)
Economic impact of medication non-adherence by disease groups: a systematic reviewBMJ Open, 8
Paul Browne, Dhia Chandraratna, Ceri Angood, H. Tremlett, C. Baker, B. Taylor, A. Thompson (2014)
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequityNeurology, 83
M. Wolf, M. Serper, Lauren Opsasnick, R. O'Conor, L. Curtis, J. Benavente, G. Wismer, S. Batio, M. Eifler, Pauline Zheng, Andrea Russell, M. Arvanitis, D. Ladner, M. Kwasny, Stephen Persell, Theresa Rowe, J. Linder, S. Bailey (2020)
Awareness, Attitudes, and Actions Related to COVID-19 Among Adults With Chronic Conditions at the Onset of the U.S. OutbreakAnnals of Internal Medicine
E. Arroyo, C. Grau, C. Ramo, J. Parra, O. Sánchez-Soliño (2010)
[Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].Neurologia, 25 7
T. Derfuss, M. Mehling, A. Papadopoulou, A. Bar-Or, Jeffrey Cohen, L. Kappos (2020)
Advances in oral immunomodulating therapies in relapsing multiple sclerosisThe Lancet Neurology, 19
C. Evans, R. Marrie, F. Zhu, S. Leung, Xinya Lu, D. Melesse, E. Kingwell, Yinshan Zhao, H. Tremlett (2016)
Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.Multiple sclerosis and related disorders, 8
D. Decoo, M. Vokaer (2015)
Treatment adherence in multiple sclerosis: a survey of Belgian neurologistsPatient preference and adherence, 9
E. Arroyo, Cai Grau, C. Ramo, J. Parra, O. Sánchez-Soliño (2010)
Estudio global de adherencia a los tratamientos inmunomoduladores en pacientes con esclerosis múltiple remitente recidivante: resultados a 2 añosNeurologia, 25
N. Camara, A. Gondim (2017)
Factors associated with adherence to immunomodulator treatment in people with multiple sclerosisBrazilian Journal of Pharmaceutical Sciences, 53
Seyed-Ali Roudbary, S. Yousefzadeh-Chabok, H. Behzadnia, Babak Bakhshayesh-Eghbali, M. Emamhadi, A. Ghayeghran, H. Hatamian, A. Saberi, S. Andalib (2017)
Non-adherence to Disease-Modifying Treatments in Patients with Multiple Sclerosis, 3
F. Alosaimi, Alaa Almulhem, Hanan Alshalan, Mohammad Alqazlan, Abdulgader Aldaif, M. Kowgier, Janooshsheya Balasundaram, S. Sockalingam (2017)
Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosisPatient preference and adherence, 11
A. Alhazzani, M. Alqahtani, N. Alamri, L. Sarhan, S. Alkhashrami, M. Alahmarii (2019)
Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi ArabiaThe Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 55
Samira Paul, A. Brown, A. Hughes (2019)
Cognitive Assessment of Individuals with Multiple Sclerosis in the Arab World: a Systematic ReviewNeuropsychology Review, 29
L. Valentino, M. Skinner, S. Pipe (2020)
The role of telemedicine in the delivery of health care in the COVID‐19 pandemicHaemophilia, 26
(1999)
Adherence to injection therapy in MS: patient survey
R. Marrie, S. Leung, T. Tyry, G. Cutter, R. Fox, A. Salter (2019)
Use of eHealth and mHealth technology by persons with multiple sclerosis.Multiple sclerosis and related disorders, 27
S. Hauser, B. Cree (2020)
Treatment of Multiple Sclerosis: A Review.The American journal of medicine
K. McKay, H. Tremlett, S. Patten, J. Fisk, C. Evans, K. Fiest, Trudy Campbell, R. Marrie (2016)
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective studyMultiple Sclerosis (Houndmills, Basingstoke, England), 23
F. Sellebjerg, M. Blinkenberg, P. Sørensen (2020)
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple SclerosisCNS Drugs, 34
A. Biderman, Enav Noff, S. Harris, N. Friedman, A. Levy (2009)
Treatment satisfaction of diabetic patients: what are the contributing factors?Family practice, 26 2
P. Wicks, M. Massagli, Amit Kulkarni, H. Dastani (2011)
Use of an Online Community to Develop Patient-Reported Outcome Instruments: The Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)Journal of Medical Internet Research, 13
Lakmini Malasinghe, N. Ramzan, K. Dahal (2017)
Remote patient monitoring: a comprehensive studyJournal of Ambient Intelligence and Humanized Computing, 10
K. Beer, Martin Müller, A. Hew-Winzeler, A. Bont, P. Maire, X. You, P. Foulds, Jessica Mårlind, Daniela Curtius (2011)
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBMC Neurology, 11
Bruno Silva, J. Rodrigues, I. Díez, Miguel Coronado, K. Saleem (2015)
Mobile-health: A review of current state in 2015Journal of biomedical informatics, 56
S. Twork, I. Nippert, P. Scherer, J. Haas, D. Pöhlau, J. Kugler (2007)
Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis populationCurrent Medical Research and Opinion, 23
G. Battista, A. Bertolotto, C. Gasperini, A. Ghezzi, D. Maimone, C. Solaro (2014)
Multiple Sclerosis State of the Art (SMART): A Qualitative and Quantitative Analysis of Therapy's Adherence, Hospital Reliability's Perception, and Services Provided QualityMultiple Sclerosis International, 2014
M. Aljumah, R. Bunyan, H. Otaibi, G. Towaijri, A. Karim, Y. Malik, M. Kalakatawi, S. Alrajeh, M. Mejally, H. Algahtani, A. Almubarak, E. Cupler, S. Alawi, S. Qureshi, S. Nahrir, A. Almalki, A. Alhazzani, I. Althubaiti, N. Alzahrani, E. Mohamednour, J. Saeedi, S. Ishak, H. Almudaiheem, A. El-Metwally, A. Al-jedai (2019)
Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive studyBMC Neurology, 20
M. Rasmi, M. Alazzam, M. Alsmadi, Ibrahim Almarashdeh, Raed Al-Khasawneh, S. Alsmadi (2018)
Healthcare professionals’ acceptance Electronic Health Records system: Critical literature review (Jordan case study)International Journal of Healthcare Management, 13
C. Evans, R. Marrie, F. Zhu, S. Leung, Xinya Lu, E. Kingwell, Yinshan Zhao, H. Tremlett (2017)
Adherence to disease‐modifying therapies for multiple sclerosis and subsequent hospitalizationsPharmacoepidemiology and Drug Safety, 26
C. Polman, S. Reingold, B. Banwell, M. Clanet, Jeffrey Cohen, M. Filippi, K. Fujihara, E. Havrdová, M. Hutchinson, L. Kappos, F. Lublin, X. Montalban, P. O'Connor, M. Sandberg-wollheim, A. Thompson, E. Waubant, B. Weinshenker, J. Wolinsky (2011)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 69
S. Zyoud, Samah Al-Jabi, W. Sweileh, D. Morisky (2013)
Relationship of treatment satisfaction to medication adherence: findings from a cross-sectional survey among hypertensive patients in PalestineHealth and Quality of Life Outcomes, 11
D. Revicki (2004)
Patient assessment of treatment satisfaction: methods and practical issuesGut, 53
Y. Chudasama, C. Gillies, F. Zaccardi, B. Coles, M. Davies, S. Seidu, K. Khunti (2020)
Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionalsDiabetes & Metabolic Syndrome, 14
V. Devonshire, Y. Lapierre, R. Macdonell, C. Ramo-Tello, F. Patti, P. Fontoura, L. Suchet, R. Hyde, I. Balla, E. Frohman, B. Kieseier (2011)
The Global Adherence Project (GAP): a multicenter observational study on adherence to disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosisEuropean Journal of Neurology, 18
S. Müller, Eya Khadhraoui, A. Khanafer, M. Psychogios, V. Rohde, L. Tanrikulu (2020)
Differentiation of arterial and venous neurovascular conflicts estimates the clinical outcome after microvascular decompression in trigeminal neuralgiaBMC Neurology, 20
M. Moccia, R. Lanzillo, V. Morra, S. Bonavita, G. Tedeschi, L. Leocani, L. Lavorgna (2020)
Assessing disability and relapses in multiple sclerosis on tele-neurologyNeurological Sciences, 41
J. Burks, T. Marshall, X. Ye (2017)
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosisClinicoEconomics and Outcomes Research: CEOR, 9
Ali Mamra, Abdul Sibghatullah, G. Ananta, M. Alazzam, Y. Ahmed, Mohamed Doheir (2017)
Theories and factors applied in investigating the user acceptance towards personal health records: Review studyInternational Journal of Healthcare Management, 10
J. Stowe, N. Andrews, E. Miller (2019)
Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain–Barré Syndrome and NarcolepsyCNS Drugs, 34
T. Klauer, U. Zettl (2008)
Compliance, adherence, and the treatment of multiple sclerosisJournal of Neurology, 255
Multiple sclerosis (MS) is a chronic autoimmune neurological disease. Disease-modifying therapies (DMTs) are mainstay lifelong treatment with no immediate benefits observed. Adherence to treatment is necessary, however, non-adherence is common problem in MS patients. This paper aims to evaluate patient-related factors and satisfactions affecting medication adherence in Saudi MS patients and their rights to discontinue them against medical advice.Design/methodology/approachIn total, 409 patients diagnosed with MS, using self-administered DMT (oral and injectable), were randomly enrolled in a cross-sectional study. Electronic questionnaire was used in data collection.FindingsMost participants (71.1%) did not know about their MS type. Average age of participants when diagnosed with MS was 27.9 ± 8 years (range 7–69), mean disease duration was 8.1 ± 6.6. Most patients received injectable therapy 363 (88%). Overall adherence in our sample was 67%. Age of participants and duration of disease had no impact on treatment adherence. No significant differences found between genders, educational level, marital status, and smoking in relation to treatment adherence. Route of administration did not reach statistical significance despite a higher percentage of adherence reported in patients on oral DMT [33% (n = 15)] versus injectable therapy [29% (n = 104)]. Conversely, there was significant difference between adherent and non-adherent patients according to anxiety (p = 0.002) and family history of MS (p = 0.011).Originality/valueThe results revealed that the age of the participants and the duration of the disease had no impact on adherence to treatment.
International Journal of Human Rights in Healthcare – Emerald Publishing
Published: Apr 12, 2022
Keywords: Saudi Arabia; Adherence; Treatment; Ehealth; Multiple sclerosis
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.